Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 322

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy

Zhang, Hai‐Liang, Yang, Li‐Feng, Zhu, Yao, Yao, Xu‐Dong, Zhang, Shi‐Lin, Dai, Bo, Zhu, Yi‐Ping, Shen, Yi‐Jun, Shi, Guo‐Hai, Ye, Ding‐Wei·2011·The Prostate

Abstract

BACKGROUND: miR‐21 has been recognized as an “onco‐microRNA” with the activity of negatively modulating the expression of tumor‐suppressor genes. However, its role in prostate cancer (CaP) has not been well‐documented. We designed this study to assess the potential function of serum miR‐21 in the progression of CaP. METHODS: Serum samples of 56 patients, including 20 patients with localized CaP, 20 with androgen‐dependent prostate cancer (ADPC), 10 with hormone‐refractory prostate cancer (HRPC), and 6 with benign prostatic hyperplasia (BPH), were collected for the measurement of miR‐21. The 10 HRPC patients were administered docetaxel‐based chemotherapy. Quantification of miR‐21 was assayed by specific TaqMan qRT‐PCR. RESULTS: Serum miR‐21 level was found to correlate to serum PSA level in patients with ADPC and HRPC, P = 0.012 and 0.049, respectively. There was no significant difference in serum miR‐21 level between BPH, localized CaP and ADPC with PSA level <4 ng/ml. Higher levels of miR‐21 were detected in patients with HRPC and ADPC with PSA level >4 ng/ml. Six of the 10 HRPC patients reached partial remission with a decreased PSA level of >50% after chemotherapy. Serum miR‐21 levels were higher in patients who were resistant to docetaxel‐based chemotherapy when compared to those sensitive to chemotherapy, P = 0.032. CONCLUSIONS: Serum miR‐21 levels are elevated in HRPC patients, especially in those resistant to docetaxel‐based chemotherapy. It may be applicable as a marker to indicate the transformation to hormone refractory disease, and a potential predictor for the efficacy of docetaxel‐based chemotherapy. Prostate 71:326–331, 2011. © 2010 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pros.21246

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 29 references

Cited by

See all 322

Metadata

Authors
Zhang, H., Yang, L., Zhu, Y., Yao, X., Zhang, S., Dai, B., Zhu, Y., Shen, Y., Shi, G., & Ye, D.
Venue
The Prostate
Publisher
Wiley
Published
2010-09-14
Volume
71
Issue
3
Pages
326-331
ISSN
  • 0270-4137 (ISSN-L)
  • 1097-0045
OpenAlex
W2030331235
Cited by
322
References
29
FWCI
8.04
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy. https://app.cochat.ai/papers/10.1002/pros.21246
The paper
Zhang, H., Yang, L., Zhu, Y., Yao, X., Zhang, S., Dai, B., Zhu, Y., Shen, Y., Shi, G., & Ye, D. (2011). Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy. The Prostate. https://doi.org/10.1002/pros.21246

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.